MX2024014961A - Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos - Google Patents

Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos

Info

Publication number
MX2024014961A
MX2024014961A MX2024014961A MX2024014961A MX2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A MX 2024014961 A MX2024014961 A MX 2024014961A
Authority
MX
Mexico
Prior art keywords
nucleic acid
nanoparticles
lipid nanoparticles
acid delivery
molecule based
Prior art date
Application number
MX2024014961A
Other languages
English (en)
Spanish (es)
Inventor
Pieter Michele Fransen
Henricus Marie Janssen
Der Meel Roy Van
Egbert Willem Meijer
Willem Jan Menno Mulder
Waal Basil Frank Maria De
Stijn Hofstraat
Original Assignee
Bio Trip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Trip B V filed Critical Bio Trip B V
Publication of MX2024014961A publication Critical patent/MX2024014961A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024014961A 2022-06-03 2024-12-02 Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos MX2024014961A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22177313 2022-06-03
PCT/EP2023/064963 WO2023233042A1 (en) 2022-06-03 2023-06-05 Polyvalent molecule based lipid nanoparticles for nucleic acid delivery

Publications (1)

Publication Number Publication Date
MX2024014961A true MX2024014961A (es) 2025-01-09

Family

ID=81940594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014961A MX2024014961A (es) 2022-06-03 2024-12-02 Nanoparticulas lipidicas basadas en moleculas polivalentes para la entrega de acidos nucleicos

Country Status (10)

Country Link
US (1) US20250325491A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531818A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025518282A (cg-RX-API-DMAC7.html)
KR (1) KR20250031158A (cg-RX-API-DMAC7.html)
CN (1) CN119522092A (cg-RX-API-DMAC7.html)
AU (1) AU2023278446A1 (cg-RX-API-DMAC7.html)
CA (1) CA3258109A1 (cg-RX-API-DMAC7.html)
IL (1) IL317412A (cg-RX-API-DMAC7.html)
MX (1) MX2024014961A (cg-RX-API-DMAC7.html)
WO (1) WO2023233042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250121393A (ko) * 2022-12-12 2025-08-12 스타르나 테라퓨틱스 표적 전달을 위한 신규 화합물 및 이의 용도
US12343429B2 (en) 2023-10-05 2025-07-01 Nanovation Therapeutics Inc. Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof
WO2025245869A1 (zh) * 2024-05-31 2025-12-04 清华大学 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途
CN119431176B (zh) * 2024-11-05 2026-02-13 汉信生物科技(苏州)有限公司 一种可电离阳离子脂质及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
KR102764250B1 (ko) 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
CN114656378A (zh) * 2016-05-16 2022-06-24 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
JP7330994B2 (ja) 2017-11-21 2023-08-22 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノ生物学的組成物による訓練免疫の促進
CN113616602B (zh) * 2021-08-31 2022-05-10 中国药科大学 一种重组高密度脂蛋白-聚酰胺-胺纳米复合物、制法及应用

Also Published As

Publication number Publication date
CN119522092A (zh) 2025-02-25
JP2025518282A (ja) 2025-06-12
US20250325491A1 (en) 2025-10-23
EP4531818A1 (en) 2025-04-09
KR20250031158A (ko) 2025-03-06
WO2023233042A1 (en) 2023-12-07
CA3258109A1 (en) 2023-12-07
IL317412A (en) 2025-02-01
AU2023278446A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
Liu et al. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease
MX2024002726A (es) Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
Lee et al. A coarse-grained model for polyethylene oxide and polyethylene glycol: conformation and hydrodynamics
MX2022012630A (es) Composicion de nanoparticulas lipidicas.
Boraschi et al. From antigen delivery system to adjuvanticy: the board application of nanoparticles in vaccinology
Thanh et al. Origanum majorana L. essential oil-associated polymeric nano dendrimer for antifungal activity against Phytophthora infestans
EA202191313A1 (ru) Композиции на основе липидных наночастиц
WO2022152109A3 (en) Lipid compounds and lipid nanoparticle compositions
BRPI0908686B8 (pt) método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
BR112022013837A2 (pt) Nanopartículas lipídicas
MX2024009361A (es) Lipidos cationicos ionizables para nanoparticulas lipidicas
CY1111491T1 (el) Βιολογικα δραστικες πρωτεϊνες που εχουν αυξημενη σταθεροτητα in vivo και/ή in vitro
Pilch et al. Foliate-targeting quantum dots-β-cyclodextrin nanocarrier for efficient delivery of unsymmetrical bisacridines to lung and prostate cancer cells
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
Zhu et al. Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen
Racles et al. Functionalized mesoporous silica as doxorubicin carriers and cytotoxicity boosters
ZA202311705B (en) Lipid compounds and lipid nanoparticle compositions
ZA202405342B (en) Lipid compounds and lipid nanoparticle compositions
Adwan et al. Chitosan nanoparticles embedded in in situ gel for nasal delivery of imipramine hydrochloride: short-term stage development and controlled release evaluation
WO2023115221A9 (en) Ionizable dilsulfide lipids and lipid nanoparticles derived therefrom
Kuznetsova et al. Complexation of oligo-and polynucleotides with methoxyphenyl-functionalized imidazolium surfactants
Yoshinaga et al. PEGylation of mRNA by hybridization of complementary PEG-RNA oligonucleotides stabilizes mRNA without using cationic materials
Sahudin et al. Enhancement of skin permeation and penetration of β-arbutin fabricated in chitosan nanoparticles as the delivery system
Calixto et al. Mucoadhesive, thermoreversible hydrogel, containing tetracaine-loaded nanostructured lipid carriers for topical, intranasal needle-free anesthesia
MX2023008363A (es) Compuestos lipidicos y composiciones de nanoparticulas lipidicas.